Literature DB >> 20594972

Clinical review about TRAb assay's history.

Klaus Zöphel1, Dirk Roggenbuck, Matthias Schott.   

Abstract

Commercial assays to measure thyroid stimulating hormone (TSH) receptor (TSHR) autoantibodies (TRAb) have been available for the serological diagnosis of autoimmune thyroid diseases (AITD) for several years. The widespread assessment of this parameter has identified Graves' disease (GD) as a common organ-specific autoimmune disease. Within the present article we aim to review immunobiological and epidemiological aspects as well as diagnostic methods available for the detection of TRAb. Over the last decade, TRAb detection in GD became more sensitive since TRAb assays were being largely improved by named research groups. Therefore, functional assay (fas) and diagnostic sensitivity of current TRAb assays will be discussed. Within the second part of this review we will focus on clinical applications of TRAb measurement for outcome prediction of GD as well as the importance of this method to distinguish GD from other AITD. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20594972     DOI: 10.1016/j.autrev.2010.05.021

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  23 in total

Review 1.  "Orbiting around" the orbital myositis: clinical features, differential diagnosis and therapy.

Authors:  F Montagnese; S Wenninger; B Schoser
Journal:  J Neurol       Date:  2015-10-17       Impact factor: 4.849

Review 2.  Selective IgA deficiency in autoimmune diseases.

Authors:  Ning Wang; Nan Shen; Timothy J Vyse; Vidya Anand; Iva Gunnarson; Gunnar Sturfelt; Solbritt Rantapää-Dahlqvist; Kerstin Elvin; Lennart Truedsson; Bengt A Andersson; Charlotte Dahle; Eva Ortqvist; Peter K Gregersen; Timothy W Behrens; Lennart Hammarström
Journal:  Mol Med       Date:  2011-08-04       Impact factor: 6.354

3.  Antithyroid peroxidase antibody positivity is associated with lower incidence of metastasis in breast cancer.

Authors:  Yasemin Kemal; Guzin Demirag; Kubilay Ekiz; Idris Yucel
Journal:  Mol Clin Oncol       Date:  2015-03-02

4.  [Hyperthyroidism].

Authors:  M Schott
Journal:  Internist (Berl)       Date:  2013-03       Impact factor: 0.743

Review 5.  Clinical review: Clinical utility of TSH receptor antibodies.

Authors:  Giuseppe Barbesino; Yaron Tomer
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

6.  High cut-off value of a chimeric TSH receptor (Mc4)-based bioassay may improve prediction of relapse in Graves' disease for 12 months.

Authors:  Sena Hwang; Dong Yeob Shin; Mi Kyung Song; Eun Jig Lee
Journal:  Endocrine       Date:  2014-06-27       Impact factor: 3.633

7.  A novel third-generation TSH receptor antibody (TRAb) enzyme-linked immunosorbent assay based on a murine monoclonal TSH receptor-binding antibody.

Authors:  Johannes J Roggenbuck; Miklos Veiczi; Karsten Conrad; Peter Schierack; Gerd Wunderlich; Joerg Kotzerke; Dirk Roggenbuck; Klaus Zöphel
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

8.  DYNAMIC CHANGES OF TRAb AND TPOAb AFTER RADIOIODINE THERAPY IN GRAVES' DISEASE.

Authors:  Q Dong; X Liu; F Wang; Y Xu; C Liang; W Du; G Gao
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Jan-Mar       Impact factor: 0.877

9.  The role of thyrotrophin receptor antibody assays in graves' disease.

Authors:  C Kamath; M A Adlan; L D Premawardhana
Journal:  J Thyroid Res       Date:  2012-04-19

10.  A patient with Graves' disease showing only psychiatric symptoms and negativity for both TSH receptor autoantibody and thyroid stimulating antibody.

Authors:  Hidetaka Hamasaki; Taro Yoshimi; Hidekatsu Yanai
Journal:  Thyroid Res       Date:  2012-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.